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Exposure to agents acting on the renin-angiotensin system was 
not associated with a risk increase of COVID-19 infection in 
2 Italian matched case-control studies, 1 nested in hypertensive 
patients and the other in patients with cardiovascular diseases 
or diabetes.
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Angiotensin-converting enzyme 2 (ACE2) is a functional re-
ceptor for severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) that facilitates the entry of the virus into the 
cells [1]. As agents inhibiting the renin-angiotensin-aldosterone 
system (RAAS) could increase the levels of ACE2, recent studies 
have raised concern over the association between these agents 
and both SARS-CoV-2 infection and illness severity [2–6]. 
Consequently, patients treated with ACE inhibitors (ACEIs) 
or angiotensin II receptor blockers (ARBs), in particular those 
with diabetes or cardiovascular disease, should be considered 
at higher risk of developing severe coronavirus disease 2019 
(COVID-19) infection (CVi), and of experiencing unfavorable 
outcomes [2, 3]. Therefore, it has been suggested that these pa-
tients should be carefully monitored or even have their therapy 
substituted with calcium channel blockers [3, 7].
However, the hypothesis of a link between agents inhibiting 
the RAAS and CVi is still under debate [7, 8], and whether 
patients should switch to other antihypertensive therapies is 
controversial. Research to clarify the role of RAAS blockade 
therapies and CVi is highly needed [7, 9].
In the first half of February 2020, the first cases of COVID-
19 infection were recorded in Italy [10], that, at present, is one 
of the leading countries in the world for both the number of 
diagnosed cases and for case fatality. Diabetes, hypertension, 
and cardiovascular diseases, conditions that are frequently 
treated with ACEIs or ARBs, are among the most prevalent 
comorbidities in these patients [11, 12].
As, to the best of our knowledge, a relationship between ACEI or 
ARB treatments and increased risk of CVi has never been demon-
strated [8], the aim of the present study was to determine whether 
an association exists between therapies based on agents acting on 
the RAAS and CVi in 2 populations at greater risk of being diag-
nosed with SARS-CoV-2 infection: hypertensive patients and pa-
tients who were affected by a cardio-cerebrovascular disease.
METHODS
Study Design and Population
We conducted 2 population-based case-control studies nested 
in 2 cohorts built using administrative data from the Piedmont 
region (4 400 000 inhabitants in northwest Italy, with a high 
rate of CVi). The population is covered by an automated system 
of databases, which record, among others, all drugs dispensed 
from all regional pharmacies, all hospital discharges, and a re-
gional register of persons with diabetes. From the beginning of 
the CVi epidemics a surveillance system was implemented to 
collect all cases identified by reverse-transcription polymerase 
chain reaction testing for SARS-CoV-2. These archives can be 
linked together by a unique anonymous identifier that is en-
crypted to protect the patient’s privacy.
The 2 case-control studies have been nested in the following 
populations, independent of each other, of patients at increased 
risk of SARS-CoV-2 infection:
1.  Circulatory diseases/diabetes (CDD): From the hospital dis-
charges, we extracted all persons aged ≥ 40 years, who were 
discharged in the previous 5 years (2015–2019) with a diag-
nosis of ischemic heart disease (International Classification of 
Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] 
code 410–414 at discharge), cerebrovascular disease (ICD-
9-CM code 430–438), or heart failure (ICD-9-CM code 428), 
and those registered in the register of persons with diabetes. 
Those living and resident in Piedmont on 31 October 2019 
represent the population base of patients with CDD.
2.  Hypertension (HY): From the drug prescription database, 
we extracted all persons aged ≥ 40 years who, in 2019, had at 
least 1 prescription of an antihypertensive drug (Anatomical 
Therapeutic Chemical Classification System [ATC] codes 
C02–C04 or C07–C09). All subjects included in the CDD 
population were excluded. Those living and resident in 
Piedmont on 31 October 2019 represent the population base 
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Selection of Cases
From the regional surveillance system, we obtained a random 
sample of 1000 confirmed cases of CVi occurring in the first 
month of the epidemic from 22 February 2020 (beginning of 
the epidemic) to 23 March 2020, who were linked to the 2 popu-
lations, to include only cases within CDD or HY.
Selection of Controls
From the same population sources, we randomly selected 
5 controls for each case, matched for year of birth and sex. CVi 
cases were ineligible for resampling as controls.
Exposure to ACEIs or ARBs
The regional drug database was used to identify cases and con-
trols who had been prescribed ACEIs or ARBs at any time from 
1 June to 31 October 2019 (last available month), considering 
ATC codes C09A or C09B for ACEIs, and C09C or C09D for 
ARBs.
Statistical Analysis
The risks of CVi associated with drug dispensation of ACEIs 
or ARBs, considered both separately and together (to take into 
account possible switch from one medication to the other), 
were estimated by fitting conditional logistic regression models, 
expressed as odds ratios (ORs) and corresponding 95% confi-
dence intervals (CIs).
To take into account the dose of medication prescribed (ie, to 
explore for a dose-response relationship), the number of boxes 
prescribed was grouped into 4 classes (0, 1–6, 7–12, and > 12).
All calculations were made using SAS version 9.4 software 
(SAS Institute, Cary, North Carolina).
RESULTS
Out of 804 909 HY and 337 059 CDD subjects, we identified 
316 and 171 cases, respectively, of CVi, who were matched 
with 1580 and 855 controls. In the HY population, 58.5% 
were male and the mean age was 71.4  years, whereas the 
mean age of the CDD population was 74.5 years and 78.4% 
were male. Among the HY population, 68.0% of cases and 
73.0% of controls had at least 1 prescription of agents acting 
on the RAAS, while among the CDD population, 54.4% of 
cases and 55.6% of controls received at least 1 prescription. 
In both populations, there were no differences between 
cases and controls by size of the municipality of residence 
(Supplementary Table).
In neither of the 2 populations was the prescription associ-
ated with the risk of SARS-CoV-2 infection. In the HY popula-
tion, ORs for ACEIs, ARBs, and the combination of the 2 were, 
respectively, 0.89 (95% CI, .70–1.15), 0.90 (95% CI, .70–1.17), 
and 0.78 (95% CI, .60–1.02). In the CDD population, ORs for 
ACEIs, ARBs, and the combination of the 2 were, respectively, 
0.92 (95% CI, .64–1.32), 1.03 (95% CI, .70–1.50), and 0.95 (95% 
CI, .68–1.34). There was no association with the level of exposi-
tion, thus excluding a dose-response relationship (Table 1).
As a sensitivity analysis, we considered that some controls 
could be unknown cases of CVi and thus a differential mis-
classification could have occurred. We repeated our analysis for 
the HY population exposed to ACEIs or ARBs (OR, 0.78) con-
sidering both 10% and 20% misclassification of controls. ORs 
showed a slight change only, to 0.81 and 0.89, respectively.
DISCUSSION
The question whether therapy with agents acting on the RAAS 
increases the susceptibility to CVi has raised concern among 
practitioners and citizens alike [2, 7], with conflicting opinions 
[8] but no sound evidence [9]. The key message of our analysis is 
that no association, regardless of causality, could be determined.
Our study has several strengths. We used a nested case-
control design enrolling both cases and controls within 2 un-
selected populations of subjects at increased risk of developing 
CVi. The consistency of ORs in these 2 independent populations 
can be viewed as a confirmation of our results. The study was 
conducted using data retrieved from the regional surveillance 
system of confirmed CVi cases. All agents acting on the RAAS 
were included, and, as they are dispensed and reimbursed only 
by prescription, we are confident to have included all dispensa-
tions. Moreover, the potential confounding due to differences in 
access to diagnosis is probably low, given no differences in the 
size of municipality.
Our study also has potential limitations. Given the high prev-
alence of undiagnosed or unknown cases of CVi in the general 
population, differential misclassification of controls is likely to 
have occurred. However, even assuming 20% of misclassifica-
tion, the ORs changed slightly, confirming the absence of asso-
ciation. Second, the use of a database of dispensed drugs rather 
than usage data might have overestimated the use ACEIs and 
ARBs; in addition, not considering the last 4 months closer to 
the onset of the disease could have slightly affected the preva-
lence of drug users; however, it is unlikely that these would have 
affected cases and controls differently. Finally, given the small 
sample size, an association between agents acting on the RAAS 
and CVi cannot be ruled out.
Despite the above limitations, at the time of this writing, our 
study is the first contribution to explore the question whether 
agents acting on RAAS increase the risk of being infected by 
SARS-CoV-2, and the first available evidence of safety of this 
class of drugs. We are aware that further epidemiological re-
search is desirable, ideally considering larger cohort studies to 
confirm our first findings. However, as studies gathering a large 
population of confirmed cases require time and may be de-
manding, smaller but more timely studies can contribute to give 
answers to urgent public health questions. Furthermore, as our 
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the risk of SARS-CoV-2 infection, the question whether RAAS 
therapy worsens the outcomes of CVi patients remains to be 
clarified.
In conclusion, on the basis of our study, as also mentioned 
by the major cardiology societies [13, 14], there is no reason to 
modify current antihypertensive therapy.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, so 
questions or comments should be addressed to the corresponding author.
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